Pyridoxal Isonicotinoyl Hydrazone (PIH) and its Analogs as Protectants Against Anthracycline-Induced Cardiotoxicity

REFERENCES

• Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove) 2000; 43(3)75–82
   PubMedGoogle Scholar
• Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130(1)1–7
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 2003; 35(11)1469–1479
   PubMedGoogle Scholar
• Simunek T, Klimtova I, Kaplanova J, Mazurova Y, Adamcova M, Sterba M, Hrdina R, Gersl V. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail 2004; 6(4)377–387
   PubMedGoogle Scholar
• Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005; 57(4)547–583
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. Comparison of deferiprone, deferoxamine, ICL670, GT56–252, L1NAll and starch deferoxamine polymers. Hemoglobin 2006; 30(2)329–347
   PubMed Web of Science ®Google Scholar
• Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, Pinson A. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 1993; 122(3)245–251
   PubMedGoogle Scholar
• Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 1994; 26(9)1179–1185
   PubMedGoogle Scholar
• Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001; 43(3)211–218
   PubMed Web of Science ®Google Scholar
• Herman EH, Zhang J, Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 1994; 35(2)93–100
   PubMedGoogle Scholar
• Barnabe N, Zastre JA, Venkataram S, Hasinoff BB. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 2002; 33(2)266–275
   PubMed Web of Science ®Google Scholar
• Xu LJ, Jin L, Pan H, Zhang AZ, Wei G, Li PP, Lu WY. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin 2006; 27(10)1333–1339
   PubMed Web of Science ®Google Scholar
• Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 1979; 97(2)317–321
   PubMed Web of Science ®Google Scholar
• Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, Paulus WJ, Musters RJ. SIH-a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 2005; 39(2)345–354
   PubMedGoogle Scholar
• Klimtova I, Simunek T, Gersl V, Hrdina R, Machackova J, Ponka P, Adamcova M, Palicka V. Biochemical and haematological changes following repeated pyridoxal isonicotinoyl hydrazone administration in rabbits. Biom Environ 2001; 4(Suppl 1)70–75
   Google Scholar
• Klimtova I, Simunek T, Mazurova Y, Kaplanova J, Sterba M, Hrdina R, Gersl V, Adamcova M, Ponka P. A study of potential toxic effects after repeated 10-week administration of a new iron chelator-salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits. Acta Medica (Hradec Kralove) 2003; 46(4)163–170
   PubMedGoogle Scholar
• Sterba M, Simunek T, Mazurova Y, Adamcova M, Popelova O, Kaplanova J, Ponka P, Gersl V. Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Hum Exp Toxicol 2005; 24(11)581–589
   PubMedGoogle Scholar
• Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 2003; 63(4)849–861
   PubMed Web of Science ®Google Scholar
• Kovarikova P, Mokry M, Klimes J, Vavrova K. HPLC study on stability of pyridoxal isonicotinoyl hydrazone. J Pharm Biomed Anal 2006; 40(1)105–112
   PubMedGoogle Scholar
• Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, Ponka P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci 2005; 28(12)1300–1306
   PubMedGoogle Scholar
• Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, Ponka P. HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 838(2)107–112
   PubMedGoogle Scholar